{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:13:16Z","timestamp":1779289996153,"version":"3.51.4"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Aims:<\/jats:bold> The study aim was to evaluate pregnancy outcomes in patients with antiphospholipid syndrome (APS) and to determine which clinical parameters present risk factors for adverse pregnancy outcomes in these patients.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods:<\/jats:bold> The study included 55 patients with APS treated at the Clinic for Ob\/Gyn, Clinical Center of Serbia, from 2006 to 2012. The control group consisted of 55 healthy pregnant women. Data regarding previous pregnancies and conception method were registered. Immunological and laboratory tests were performed. Pregnancy outcomes, including miscarriage, intrauterine fetal death, hypertensive disorders, diabetes mellitus, phlebothrombosis, fetal growth restriction, premature delivery, delivery method, perinatal asphyxia, respiratory distress syndrome, intraventricular hemorrhage, and necrotizing enterocolitis were followed.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results:<\/jats:bold> The premature delivery rate in APS patients was 31.8%, and pregnancy loss was 18.2%. Significantly more patients with APS had thrombocytopenia, pregnancy losses, intrauterine growth restriction, and perinatal asphyxia compared with the control group. More miscarriages, preterm delivery, lower birth weight, preeclampsia, and IgM anticardiolipin antibody levels significantly correlated with adverse pregnancy outcomes. Although rare, respiratory distress syndrome can also worsen neonatal health status. According to ROC analysis, previous miscarriages correctly explained 66.3% of adverse pregnancy outcome cases. We generated four equations of adverse pregnancy outcome risk factors.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions:<\/jats:bold> The most important prognostic factor for pregnancy outcome in APS patients is the number of previous miscarriages. Using appropriate current therapeutic protocol can enable live birth of a healthy newborn in most cases.<\/jats:p>","DOI":"10.1515\/jpm-2014-0118","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T17:01:42Z","timestamp":1446742902000},"page":"761-768","source":"Crossref","is-referenced-by-count":20,"title":["Neonatal outcome in pregnant patients with antiphospholipid syndrome"],"prefix":"10.1515","volume":"43","author":[{"given":"Katarina","family":"Jeremic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Stefanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Dotlic","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Clinical Centre of Serbia, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Stojnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasa","family":"Kadija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Vilendecic","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Clinical Centre of Serbia, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tijana","family":"Janjic","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Clinical Centre of Serbia, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Jeremic","sequence":"additional","affiliation":[{"name":"Clinic for Plastic and Reconstructive Surgery, Clinical Center of Serbia, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"2023031403251248512_j_jpm-2014-0118_ref_001_w2aab2b8c35b1b7b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"Blank M, Shoenfeld Y. Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome. Clin Rev Allergy Immunol. 2010;38:141\u20137.10.1007\/s12016-009-8146-x19562524","DOI":"10.1007\/s12016-009-8146-x"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_002_w2aab2b8c35b1b7b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Bramham K, Hunt BJ, Germain S, Calatayud I, Khamashta MA, Bewely S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19:58\u201364.10.1177\/096120330934779419897518","DOI":"10.1177\/0961203309347794"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_003_w2aab2b8c35b1b7b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management and controversies. Obstet Gynecol. 2003;101:1333\u201344.","DOI":"10.1097\/00006250-200306000-00031"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_004_w2aab2b8c35b1b7b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"Cervera R, Piette JC, Font J, Khamasta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002;46:1019\u201327.10.1002\/art.1018711953980","DOI":"10.1002\/art.10187"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_005_w2aab2b8c35b1b7b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramon E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2013 doi:10.1136\/annrheumdis-2013-204838.10.1136\/annrheumdis-2013-20483824464962","DOI":"10.1136\/annrheumdis-2013-204838"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_006_w2aab2b8c35b1b7b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Clark EAS, Silver RM, Branch W. Do Antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9:219\u201325.10.1007\/s11926-007-0035-917531175","DOI":"10.1007\/s11926-007-0035-9"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_007_w2aab2b8c35b1b7b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"Cohen D, Buurma A, Goemaere NN, Girardi G, le Cessie S, Scherjon S, et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol. 2011;225:502\u201311.10.1002\/path.289321688269","DOI":"10.1002\/path.2893"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_008_w2aab2b8c35b1b7b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"Danza A, Ruiz-Iratostra G, Khamashta M. Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynecol. 2012;26:65\u201376.10.1016\/j.bpobgyn.2011.10.00622079775","DOI":"10.1016\/j.bpobgyn.2011.10.006"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_009_w2aab2b8c35b1b7b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"De Jesus GR, Rodrigues G, de Jesus NR, Levy RA. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16:403.10.1007\/s11926-013-0403-624390757","DOI":"10.1007\/s11926-013-0403-6"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_010_w2aab2b8c35b1b7b1ab2ac10Aa","unstructured":"Di Prima FA, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E, et al. Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med. 2011;5:41\u201353."},{"key":"2023031403251248512_j_jpm-2014-0118_ref_011_w2aab2b8c35b1b7b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Di Simone N, Castellani R, Raschi E, Borghi MO, Meroni PL, Caruso A. Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. Ann NY Acad Sci. 2006;1069:364\u201376.10.1196\/annals.1351.03416855163","DOI":"10.1196\/annals.1351.034"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_012_w2aab2b8c35b1b7b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;2:CD002859.10.1002\/14651858.CD002859.pub2676898715846641","DOI":"10.1002\/14651858.CD002859.pub2"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_013_w2aab2b8c35b1b7b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"Giannakopoulos B, Krilis SA. The Pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033\u201344.10.1056\/NEJMra111283023484830","DOI":"10.1056\/NEJMra1112830"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_014_w2aab2b8c35b1b7b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"Harper BE, Willis R, Pierangeli SS. Pathophysiologial mechanisms in antiphospholipid syndrome. J Clin Rheumatol. 2011;6:157\u201371.10.2217\/ijr.11.9359324623487578","DOI":"10.2217\/ijr.11.9"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_015_w2aab2b8c35b1b7b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Kutteh WH, Hinote CD. Antiphospholipid antibody syndrome. Obstet Gynecol Clin North Am. 2014;41:113\u201332.10.1016\/j.ogc.2013.10.00424491987","DOI":"10.1016\/j.ogc.2013.10.004"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_016_w2aab2b8c35b1b7b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Le Thi Thuong D, Tieulie N, Costedoat N, Andreu MR, Wechsler B, Vauthier-Brouzes D, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis. 2005;64:273\u20138.10.1136\/ard.2003.019000175535815647435","DOI":"10.1136\/ard.2003.019000"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_017_w2aab2b8c35b1b7b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Mak IY, Brosens JJ, Christian M, Hills FA, Chamley L, Regan L, et al. Regulated expression of signal transducer and activator of transcription, Stat5, and its enhancement of PRL expression in human endometrial stromal cells in vitro. J Clin Endocrinol Metab. 2002;87:2581\u20138.10.1210\/jcem.87.6.857612050218","DOI":"10.1210\/jcem.87.6.8576"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_018_w2aab2b8c35b1b7b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Marchetti T, Cohen M, de Moerloose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications. Clin Dev Immunol. 2013;doi:10.1155\/2013\/159124.10.1155\/2013\/159124374590423983765","DOI":"10.1155\/2013\/159124"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_019_w2aab2b8c35b1b7b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Matsubayashi H, Sugi T, Arai T, Shida M, Kondo A, Suzuki T, et al. IgG-antiphospholipid antibodies in follicular fluid of IVF-ET patients are related to low fertilization rate of their oocytes. Am J Reprod Immunol. 2006;55:341\u20138.10.1111\/j.1600-0897.2006.00374.x16635208","DOI":"10.1111\/j.1600-0897.2006.00374.x"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_020_w2aab2b8c35b1b7b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"Mulla MJ, Myrtolli K, Brosens JJ, Chamley LW, Kwak-Kim JY, Paidas MJ, et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol. 2010;63:339\u201348.10.1111\/j.1600-0897.2009.00805.x20132164","DOI":"10.1111\/j.1600-0897.2009.00805.x"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_021_w2aab2b8c35b1b7b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"Myakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295\u2013308.10.1111\/j.1538-7836.2006.01753.x16420554","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_022_w2aab2b8c35b1b7b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titres and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth. 2009;9:11.10.1186\/1471-2393-9-11266279019291321","DOI":"10.1186\/1471-2393-9-11"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_023_w2aab2b8c35b1b7b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"Qublan HS, Eid SS, Ababneh HA, Amarin ZO, Smadi AZ, Al-Khafaji FF, et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod. 2006;21:2694\u20138.10.1093\/humrep\/del20316835215","DOI":"10.1093\/humrep\/del203"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_024_w2aab2b8c35b1b7b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"Sanmarco M, Bardin N, Camoin L, Beziane A, Dignat-George F, Gammere M, et al. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann NY Acad Sci. 2007;1108:457\u201365.10.1196\/annals.1422.04817894010","DOI":"10.1196\/annals.1422.048"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_025_w2aab2b8c35b1b7b1ab2ac25Aa","unstructured":"Serrano F, Nogueira I, Borges A, Branco J. Primary antiphospholipid syndrome: pregnancy outcome in a Portugese population. Acta Reumatol Port. 2009;34:492\u201397."},{"key":"2023031403251248512_j_jpm-2014-0118_ref_026_w2aab2b8c35b1b7b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"Stone S, Hunt BJ, Khamashta MA, Bewely SJ, Nelson-Piercy C. Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost. 2005;3:243\u20135.10.1111\/j.1538-7836.2005.01185.x15670028","DOI":"10.1111\/j.1538-7836.2005.01185.x"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_027_w2aab2b8c35b1b7b1ab2ac27Aa","doi-asserted-by":"crossref","unstructured":"Tincani A, Lojacono A, Taglietti M, Motta M, Biasini C, Decca L, et al. Pregnancy and neonatal outcome in antiphospholipid syndrome. Lupus. 2002;11:649.10.1191\/0961203302lu269oa12413058","DOI":"10.1191\/0961203302lu269oa"},{"key":"2023031403251248512_j_jpm-2014-0118_ref_028_w2aab2b8c35b1b7b1ab2ac28Aa","doi-asserted-by":"crossref","unstructured":"Van Horn JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta. 2004;25:642\u20138.10.1016\/j.placenta.2003.12.00615193871","DOI":"10.1016\/j.placenta.2003.12.006"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2014-0118\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2014-0118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:29:31Z","timestamp":1678764571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2014-0118\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,8,19]]},"published-print":{"date-parts":[[2015,11,1]]}},"alternative-id":["10.1515\/jpm-2014-0118"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2014-0118","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}